News Release(2007)

September 28, 2007

Kissei and Eisai sign a license agreement to develop and commercialize Glufast® a rapid-acting insulin secretagogue in China

September 26, 2007

Results of a Phase III Double-blinded Comparative Study of Silodosin (Brand name in Japan: Urief®) conducted in Europe

July 23, 2007

Kissei Entered into an Agreement with Nuon Therapeutics, Inc on Tranilast (Product Name: Rizaben®)

June 12, 2007

Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in 10 ASEAN countries

May 24, 2007

Approval of an Additional Indication of Combination Therapy of Glufast® and Alpha-glucosidase Inhibitor in Japan

April 24, 2007

Construction of Joetsu Chemical Laboratory Completed

April 23, 2007

Application for an Additional Indication of Combination Therapy of Glufast® and Insulin Sensitizer in Japan

January 17, 2007

Results of US Phase III Double-blind Comparative Studies of Silodosin (Brand name in Japan: Urief®)